84 articles - From Friday Mar 27 2026 to Friday Apr 03 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
|---|
| Meta-Analysis: Prevalence and Incidence of Gastroparesis Following Lung or Heart Transplantation.
Gastroparesis affects nearly one-third of thoracic transplant recipients, with a numerically higher burden after HLT transplantation. There was no association between age and gender and the prevalence of post-transplant gastroparesis. |
| Systematic Review: Imaging-Based Morphological Criteria for Liver Cirrhosis-A Call to Standardise.
Despite the widespread use of cross-sectional imaging in cirrhosis, there is no consensus-based, standardised imaging definition. This highlights the urgent need for a standardised, morphology-based definition of cirrhosis. |
| Gastrointest Endosc |
| Endoscopic Submucosal Dissection for Locally Recurrent Gastric Neoplasia Following Endoscopic Resection: A Systematic Review and Meta-Analysis.
ESD for locally recurrent gastric neoplasia after ER achieves acceptable curative resection, high en bloc/R0 resection, and low local recurrence and morbidity. It is a viable organ-preserving option for appropriately selected patients, ideally performed at expert centers with close surveillance. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311).
The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile. |
| Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.
Plozasiran significantly lowered circulating TG levels, with substantial reduction in recurrent AP for participants with very severe hypertriglyceridemia and history of AP. Plozasiran is the first therapy to demonstrate a statistically significant reduction in recurrent AP in a prospective randomised trial of patients with familial chylomicronaemia syndrome (FCS). |
| Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia.
In this analysis of US administrative claims data, individuals with HBV-LLV had a significantly increased risk of liver-related events compared with those without evidence of HBV. Additional research is needed to identify risk stratification and mitigation strategies, including earlier antiviral treatment. |
| Sarcopenia Is Associated With Mortality and Progression of Cirrhosis in Decompensated but Not Compensated Disease-A Multicentre Study.
Sarcopenia was independently associated with cirrhosis progression or death and death alone in decompensated cirrhosis. Future studies are needed to evaluate the possibility of slowing cirrhosis disease progression by reversing or preventing sarcopenia. |
| Am J Gastroenterol |
| A Randomized Trial Testing a Body-Focused Exposure Treatment for Functional Abdominal Pain in Children.
Both the FBI and CIA interventions reduced pain and improved emotional functioning in young children with FAP. Although the two approaches differed in their focus on attention to pain and use of exposure strategies, they were not significantly different. These findings provide pediatricians and mental health providers with evidence-based options for treating young children with FAP. |
| Comparative safety of Potassium-competitive acid blockers on the risk of clostridium difficile infection: a multicenter cohort study.
In this cohort study, P-CAB use was not associated with a higher risk of CDI compared to PPIs or H2RAs. |
| Early life intake of marine n-3 fatty acids, genetic fatty acid desaturase variants, and risk of celiac disease.
Overall, there was no evidence that the total intake of marine n- 3 fatty acids in early life was associated with a lower risk of CeD. Instead, data suggested an association in the positive direction for the child's genotypes resulting in higher EPA and DHA status, and EPA and DHA supplements during pregnancy, with child CeD risk. |
| Temporal Trends in Hepatitis C Virus (HCV) Screening and Management in Pregnant Women and Infants between 2014 - 2024 in San Francisco, California.
Despite increasing screening over time, substantial gaps persist in HCV screening, follow-up testing, and linkage to care for pregnant patients and their infants. High loss to follow-up and low infant screening rates highlight the urgent need to strengthen peripartum HCV care pathways to support maternal and pediatric cure and advance HCV elimination goals. |
| Clin Gastroenterol Hepatol |
| Association between index adenomas and advanced findings at third colonoscopy: Data from the New Hampshire Colonoscopy Registry.
Our analysis demonstrated that patients with advanced adenomas or 5+ adenomas on index exam and a normal 1 st surveillance exam have increased risk for advanced findings on second surveillance colonoscopy. This association is independent of quality measures including ADR and known risk factors such as smoking and BMI. |
| Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic era.
Postoperative recurrence risk can be estimated using a model based on clinical factors. Biologic prophylaxis is highly effective in preventing early endoscopic recurrence, regardless of risk profile. |
| Disparities in Healthcare Seeking and Physician Diagnosis of Irritable Bowel Syndrome: Results from a US Survey.
Among respondents meeting Rome IV IBS criteria, significant sex and racial disparities in healthcare-seeking behavior and HCP-based IBS diagnosis rates were observed. Further research is needed to understand the reasons underlying these disparities and implications on patient care and health outcomes. |
| Natural language processing algorithm accurately classifies diverticulitis-related complications and predicts long-term outcomes.
Our NLP algorithm accurately classifies diverticulitis features, facilitating the construction of large and high-quality EHR-based cohorts. Severity at initial diagnosis predicts risk of severe recurrence, supporting the use of artificial intelligence for risk stratification and long-term management. |
| ORP-101 in Irritable Bowel Syndrome with Diarrhea: A Phase II Randomized, Controlled Trial.
In this phase II trial, ORP-101 100 mg did not achieve a statistically significant difference vs placebo for the primary endpoint; however, it showed higher response across multiple key endpoints. Future studies will study ORP-101 in other chronic pain conditions. |
| Timing of Direct Oral Anticoagulant Resumption After Outpatient Colonoscopy and Risk of Gastrointestinal Bleeding and Thromboembolic Events.
After elective colonoscopy, delayed DOAC resumption was associated with increased thromboembolic risk without a corresponding reduction in GI bleeding, suggesting thromboembolism risk may warrant greater consideration when determining resumption timing. |
| Endoscopy |
| Endoscopic ultrasound versus endoscopic retrograde cholangiopancreatography for primary palliation of malignant distal biliary obstruction: a cost-effectiveness modeling analysis.
In one-way sensitivity analyses, EUS-CDS remained cost effective if it cost 15 mm, EUS-CDS with LAMS may be not only a clinically preferred option but also an economically viable primary approach. Continued efforts to minimize LAMS costs, decrease stent dysfunction, and identify optimal anatomic indications are warranted to facilitate wider adoption. |
| Gastroenterology |
| A Randomized Double-Blind, Placebo-Controlled Dose-Response Study to Assess the Gluten Threshold Dose in Celiac Disease.
Acute interleukin-2 release occurs at gluten doses below current food-labelling thresholds. Symptoms are unreliable at exposures <1000 mg. These findings provide a framework for defining exposure limits based on immune activation. (ACTRN12621000781842, registered 22/06/2021). |
| DNA/RNA-Based Next-Generation Sequencing (NGS) Improves the Early Diagnosis and Management of Neoplastic Bile Duct Strictures: A Six-Year, Prospective, Multi-Institutional, Real-Time Study.
Applying BiliSeqV2/V3 testing to ERCP-obtained specimens improved the diagnostic evaluation of bile duct strictures, achieving higher sensitivity, especially for PSC, and maintained high specificity compared to traditional methods. This study highlights the importance of NGS for precise diagnosis and therapeutic intervention. |
| The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.
Optimizing H. pylori treatment requires evidence-based regimen selection, precision-guided strategies, antimicrobial stewardship and equitable access to essential medications. Advances in molecular diagnostics, antimicrobial development, and implementation science are al critical to reducing the global burden of H. pylori-associated disease and gastric cancer. |
| Gastrointest Endosc |
| Clinical Outcomes of Circumferential Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma: A Retrospective Study.
C-ESD is an effective treatment for C-ESCCs. While it achieves reliable oncological control with favorable prognosis, its value is tempered by high stricture rates and a non-negligible recurrence risk (∼20%). To optimize patient outcomes, advancing stricture prevention and ensuring rigorous long-term management are crucial future directions. |
| EUS-guided radiofrequency ablation for intraductal papillary mucinous neoplasms with worrisome features : long-term outcomes in non-surgical patients.
EUS-RFA is feasible, safe, and provides durable local control of BD-IPMNs with WF/HRS in patients unsuitable for surgery or declining resection. These results support EUS-RFA as a promising therapeutic option in carefully selected patients. Larger prospective studies are needed to refine selection criteria and confirm long-term oncologic benefit. |
| Outcomes of Peroral Endoscopic Myotomy in Patients With Cirrhosis: A Multicenter Focused Communication.
In this highly selected cohort treated at experienced centers, POEM was feasible and associated with symptomatic improvement without observed major bleeding. These findings represent an early experience and should be interpreted cautiously. |
| Gut |
| Commonly prescribed drugs as risk factors for <i>Clostridioides difficile</i> infections: a Swedish population-based case-control study.
We found varying effects of antibiotics on CDI, providing evidence for ongoing efforts in prudent prescribing decisions and antimicrobial stewardship. We confirmed PPI as a main risk factor for CDI and provided new evidence for other non-antibiotic drugs as potentially important risk factors considering their high prescription prevalence. |
| Selenoprotein P deficiency drives hepatocellular carcinoma progression via induction of neutrophil senescence and immunosuppressive microenvironment.
Sepp1 is a key regulator of neutrophil senescence-associated reprogramming and immune suppression in HCC through selenium-dependent epigenetic remodelling. Targeting senescent-like neutrophils via selenium supplementation holds therapeutic promise to enhance immunotherapy efficacy in liver cancer. |
| Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.
The non-invasive two-step approach of FIB-4 followed by LSM effectively stratifies MASLD-related advanced fibrosis and LREs risk in T2D. Applying LSM cut-offs of 10 and 15 kPa further optimises risk stratification for future LREs. |
| Hepatology |
| Forkhead box protein M1 network induction and crosstalk drives the development of alcohol-associated liver disease.
Taken together, FOXM1 is activated in hepatocytes in response to EtOH through a mechanism that involves PKCε, MEK/ERK, cyclin D1-CDK4/6, PIN1, and GRN. Targeting this pathway may represent a novel therapeutic strategy for ALD. |
| HSP72 interacts with PRDX6 to deubiquitinate mitochondrial PINK1, activating mitophagy to treat MASLD.
These data suggest that the HSP72/PRDX6 axis is indispensable for PINK1/Parkin-dependent mitophagy to counteract MASLD. |
| Intravenous albumin after outpatient paracentesis reduces the risk of AKI hospitalization: A national cohort study.
Albumin administration after outpatient paracentesis was associated with a reduced risk of hospitalization with AKI, with a greater effect at lower estimated glomerular filtration rates. Strategies that tailor albumin administration based on intravascular volume and hemodynamics should be prospectively tested. |
| Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction-Associated Steatohepatitis (MASH).
This synthetic review aims to provide a roadmap for federal regulators updating and potentially revising the requirements for demonstrating histologic improvement in MASH clinical trials, and for practitioners to translate this information into clinical practice. The ultimate goal is to reduce the reliance on liver biopsy while maintaining the rigor necessary to evaluate therapeutic efficacy, thus accelerating the path to approval for new MASH treatments. |
| Parallel regulation of goblet cell-associated antigen passages by reduced microbial sensing and mAChR4 signaling in Muc2 deficiency prevents ethanol-induced liver injury.
GAPs are central to gut-liver homeostasis. Mucin-2 deficiency enhances GAP formation and confers protection against ALD, whereas GAP closure exacerbates disease. Targeting GC-specific mAChR4 to restore GAPs represents a promising therapeutic strategy for ALD. |
| Pathogenic Ifit1+ neutrophils driven by IRF7 promote liver injury and represent a therapeutic target in acute liver failure.
These findings delineate an IRF7-Ifit1+ neutrophil-FGL2 axis driving ALF pathogenesis and establish its targeted inhibition as a viable therapeutic strategy. |
| RNF128 aggravates metabolic dysfunction-associated steatotic liver disease progression via stabilization of SCD1.
Our study establishes the RNF128-SCD1 axis as a central mechanism in MASLD and highlights its therapeutic potential. |
| Therapeutic plasma exchange improves short-term survival in patients with acute-on-chronic liver failure: A randomized controlled trial.
Interpretation TPE significantly improves 28-day survival and organ failure resolution in patients with ACLF, but does not reduce 90-day mortality. [CTRI/2022/01/039094]. |
| J Hepatol |
| Activated hepatic stellate cells maintain liver bile acid homeostasis through paracrine FGF10/FGFR2 signaling.
Our study identifies a critical role for aHSCs in the regulation of hepatic BA homeostasis, demonstrating that aHSCs and the associated FGF10/FGFR2 signaling may act as potential therapeutic targets in cholestasis. Impact and implications Cholestasis and MASH are associated with the activation of HSCs, yet whether HSCs influence bile acid metabolism during these processes remains largely unknown. Here, we demonstrate that murine activated HSCs control CYP7A1 expression in hepatocytes via paracrine FGF10, which inhibits primary BA synthesis in obstructive cholestasis and MASH. Paracrine FGF10/FGFR2 signaling controls hepatic primary BA synthesis and alleviates ductular reaction and liver injury in cholestatic mice, but showed no significant effect on steatosis and fibrosis during MASH progression. This study implies specific roles for activated HSCs and FGF10 in the maintenance of hepatic BA homeostasis in. |
| Global patterns of mutational profiles in biliary tract cancer.
This cross-study integrative analysis provides an international view of BTC genomics, codifying how geography, etiology, and anatomical subtype together shape driver landscapes. Impact and implications Our results provide statistical depth, uncover new mutational relationships, and suggest high-priority avenues for basic and translational research. In total, our findings serve as a basis for future basic and translational research and clinical trial design that are sensitive to geography, etiology, specific mutations, and co-mutation landscapes. |
| Liver Sinusoidal Endothelial Cells and Laminin dictate cholangiocytes' fate in chronic liver disease.
Capillarized CD34+ LSECs maintain the biliary phenotype of DR cells by preventing laminin degradation, thereby limiting their differentiation into hepatocytes. Targeting this axis could enhance liver regeneration and improve outcomes in chronic liver disease. Impact and implications Chronic liver disease progression is characterized by impaired hepatocyte regeneration, making alternative regenerative pathways such as DR-driven hepatocyte formation of particular interest. This study provides mechanistic insight into how the local microenvironment specifically capillarized CD34 + LSECs and laminin deposition restricts DR plasticity by stabilizing a biliary fate, thereby limiting endogenous regeneration. These findings are relevant for researchers investigating liver regeneration, fibrosis, and cholangiopathies, and for clinicians seeking to understand why regenerative responses remain inefficient in advanced disease. While acknowledging that DR-derived hepatocytes contribute modestly to overall parenchymal renewal, our results suggest that therapeutically modulating LSEC capillarization or ECM remodeling could represent a strategy to enhance regenerative competence in chronic liver disease, warranting further preclinical and translational investigation. |
| Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.
At 10 years, 17% of patients achieved off-treatment HBsAg loss, whereas more than half has been retreated. Patients with HBsAg levels <100 IU/mL benefit the most from NA cessation with a HBsAg loss rate of 52%. Based on our data, finite NA therapy is not recommended if HBsAg ≥1,000 IU/mL or in cirrhotic patients. Impact and implications Based on our study, we can conclude that finite NA therapy can be considered in patients with HBsAg levels <100 IU/mL when aiming for HBsAg loss, since they have the highest likelihood of achieving this endpoint (52%) and lowest need for retreatment (28%) during long-term follow-up, but only when strict monitoring can be guaranteed. In contrast, finite therapy is not recommended in patients with HBsAg levels ≥1,000 IU/mL or those with a history cirrhosis, especially as cirrhosis is a known risk factor for hepatic decompensation and HCC. In addition, our data can be used to further improve patient monitoring after finite NA therapy, especially in those who successfully remain off-therapy for five to ten years. Clinical trial number not applicable. |
| Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.
Resmetirom treatment led to significant improvements in qFC, qFS, and individual collagen features associated with fibrosis progression. These digital pathology findings support the antifibrotic efficacy of resmetirom and demonstrate the potential of AI-based quantification to help define the fibrogenic response in MASH. Impact and implications This study provides the first evidence that AI-based digital pathology, including qFibrosis and region-specific collagen features, sensitively detects antifibrotic treatment effects of resmetirom in MASH beyond the conventional ordinal staging based on a phase 3 pivotal trial. These continuous metrics highlight nuanced pathophysiological mechanisms of fibrosis progression and reversal in MASLD including early matrix remodeling and allowing for more granular, reproducible, and biologically plausible analysis. The ability to quantify spatially distinct collagen remodeling patterns, especially in portal tract and Zone 2 regions, could help refine the understanding of the anti-fibrotic effects of treatment for MASH including the impact to reduce fibrosis progression to cirrhosis and clinical outcomes. Clinical trial number NCT03900429. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. |
| Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention. |
| Editorial: Low-Level Viraemia in Chronic Hepatitis B-A Benign State or Missed Opportunity? |
| Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. |
| Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.
Isoform selectivity contributes to the efficacy and safety profiles of PPAR agonists. Future research should investigate isoform-specific mechanisms, particularly regarding symptom relief and agent- and class-related toxicities. |
| Gastroenterology |
| From Autoimmunity to Intestinal Tissue Damage: Insights From Potential Celiac Disease as a Paradigm of Disease Progression.
In conclusion, PCD represents a heterogeneous but highly informative condition positioned at the crossroads between genetic susceptibility and mucosal damage. The identification of reliable progression markers and the development of targeted preventive interventions could transform CeD management and contribute broadly to the understanding and prevention of organ-specific autoimmunity. |
| Re-induction or Redirection? Lessons From the REScUE Trial on Ustekinumab Intensification in Crohn's Disease. |
| J Hepatol |
| Refining the Definition of ACLF - keeping score and changing the game. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Correction to: Stool Testing for Colon Cancer: Growing Options. |
| Extraluminal esophageal stent misdeployment: a complication of managing an esophageal perforation. |
| Clin Gastroenterol Hepatol |
| Associations of Lifestyle Factors and Ultra-Processed Food Consumption with Constipation Among US Adults: NHANES 2005-2010. |
| Endoscopy |
| A novel assisted technique for difficult 24-hour esophageal pH-impedance probe placement. |
| A rare case of calcifying fibrous tumor treated with endoscopic full-thickness resection. |
| An unexpected extraluminal foreign body. |
| Endobiliary radiofrequency ablation to remove embedded metal stents. |
| Endoscopic ultrasound-directed transenteric retrograde cholangiopancreatography with cholangioscopy-guided argon plasma coagulation for removal of uncovered metal stents. |
| Enhanced visualization of flat gastric dysplasia by chromoendoscopy using an acetic acid-indigocarmine mixture. |
| Gastroscope-assisted endoscopic retrograde cholangiopancreatography with duodenal retroversion for management of recurrent biliary stent obstruction in malignant duodenal stricture. |
| Guidewire passage through metal stent mesh using a novel sphincterotome during the stent-in-stent technique. |
| Peroral choledochoscope in the diagnosis of double common bile duct. |
| Targeted endoscopic ultrasound-guided vascular angiotherapy for refractory upper gastrointestinal bleeding due to an aberrant collateral vessel. |
| Gastroenterology |
| A Mysterious Case of Diffuse Severe Hepatic Steatosis in a Thin Teenager. |
| Curbside Consult, Refractory Gastric Ulceration. |
| Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis. |
| Metabolomic pattern of ultra-processed food intake and risk of colorectal cancer precursors. |
| Peripheral Eosinophilia in a Patient With Subacute Watery Diarrhea. |
| Gut |
| Acute abdomen after endoscopic treatment of caecal angiodysplasia. |
| J Hepatol |
| The limits of lifestyle in metabolic disease: How the microbiome shapes exercise response. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply. |
| Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply. |
| Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? |
| Letter: Beyond Association: Operationalizing PRS-5 for Hepatocellular Carcinoma Surveillance. Authors' Reply. |
| Letter: Circulating CD4<sup>+</sup>PD-1<sup>+</sup>T Cell Ratio Predicts Response to Pegylated Interferon-Alpha Therapy in Chronic Hepatitis B. |
| Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease - Expanding Strategies Beyond Double-Dose Recombinant Vaccination. |
| Letter: Steroid Tapering-Is Shorter Duration Better? Authors' Reply. |
| Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity. |
| Clin Gastroenterol Hepatol |
| "EUS-PPG in Clinical Practice: An Investigational Procedure - What Can We Tell Patients?" |
| On the effectiveness and cost-effectiveness of novel noninvasive colorectal cancer screening tests. |
| Reply: Cost-effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia. |
| Gastroenterology |
| Avoidant/restrictive food intake disorder in disorders of gut-brain interaction: adaptive restriction or psychopathology? |
| Comment on "Esophageal Hypervigilance and Anxiety Predict Post-Treatment Outcomes in Achalasia". |
| Gastrointest Endosc |
| Is the combination of rectal indomethacin and pancreatic stenting truly necessary for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. |
| J Hepatol |
| Clonal T Cell Responses in CASH: Implications for Liver Metastasis. |
| Early Abstinence, Socioeconomic Barriers, and Survival in Decompensated Alcohol-Related Cirrhosis: A Real-World Cohort from China. |